PMED Stock Overview A pharmaceutical company, researches, develops, and sells medical treatments and lifestyle products in the field of women's health. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
PEPTONIC medical AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for PEPTONIC medical Historical stock prices Current Share Price SEK 0.06 52 Week High SEK 0.13 52 Week Low SEK 0.05 Beta 0.18 1 Month Change 0% 3 Month Change 0% 1 Year Change -27.71% 3 Year Change -95.15% 5 Year Change -92.95% Change since IPO -99.43%
Recent News & Updates
PEPTONIC medical AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025 Jan 30
Peptonic Medical AB (Publ) Launches New Product for Relief of Epitation in the External Intimate Area Jan 24
Peptonic Medical AB (publ) Announces Launch of its In-House Lubricant, VagiVital Active Glide Jan 15
Peptonic Medical Appoints Jacob Eriksson as Board Member Jan 09
Peptonic Medical AB (publ) Strengthens U.S. Market Presence with Full-Scale Launch of VagiVital Nov 05
PEPTONIC medical AB (publ) to Report Q3, 2024 Results on Nov 06, 2024 Oct 08 See more updates
PEPTONIC medical AB (publ) to Report Fiscal Year 2024 Results on Feb 28, 2025 Jan 30
Peptonic Medical AB (Publ) Launches New Product for Relief of Epitation in the External Intimate Area Jan 24
Peptonic Medical AB (publ) Announces Launch of its In-House Lubricant, VagiVital Active Glide Jan 15
Peptonic Medical Appoints Jacob Eriksson as Board Member Jan 09
Peptonic Medical AB (publ) Strengthens U.S. Market Presence with Full-Scale Launch of VagiVital Nov 05
PEPTONIC medical AB (publ) to Report Q3, 2024 Results on Nov 06, 2024 Oct 08
PEPTONIC medical AB (publ) to Report Q2, 2024 Results on Aug 13, 2024 Jul 15
Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038 Jul 03
Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch May 31
PEPTONIC medical AB (publ) Announces Chief Financial Officer Changes May 16
PEPTONIC medical AB (publ), Annual General Meeting, May 21, 2024 Apr 17
PEPTONIC medical AB (publ) to Report Q1, 2024 Results on May 07, 2024 Apr 08
PEPTONIC medical AB (publ) Announces Resignation of Albert Lindgren as CFO Mar 28
Peptonic Medical AB (Publ) Announces Patented Apoteket Offering in 293 Apoteket Stores Dec 19
Third quarter 2023 earnings released Oct 25
Second quarter 2023 earnings released Aug 13
Peptonic Medical AB (Publ) Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023 Aug 02
District Court Rejects the Claim for A Corporate Fine and Acquits All in Insider Case Against Peptonic Medical AB (Publ) Jun 29
PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million. Jun 17
Pharmiva AB (publ) (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB (publ) (NGM:PMED). Jun 16
Peptonic Medical AB (Publ) Announces the Application to Patent Its Intimate Cleaner in US to Be Approved on June 20, 2023 Jun 14
Less than half of directors are independent May 29
First quarter 2023 earnings released Apr 26
Full year 2022 earnings released: kr0.15 loss per share (vs kr0.39 loss in FY 2021) Feb 25
High number of new and inexperienced directors Nov 16
PEPTONIC medical AB (publ) Ongoing Applications for the Intimate Wash and for the Treatment of Fungal Infection Has Received Positive Statements from the International Review Nov 05
Peptonic Medical AB (Publ) Announces Vagivital® Al Self-Test for Amniotic Fluid Leakage Detection Is Now Commercially Available for Sale in Its Own Online Store Sep 28
Peptonic Medical's Ongoing Application for Vestibulitis Patent Receives Positive Opinion from the International Review Sep 03
Second quarter 2022 earnings released: kr0.037 loss per share (vs kr0.064 loss in 2Q 2021) Aug 21
High number of new and inexperienced directors May 31
First quarter 2022 earnings released May 14
No independent directors Apr 27
Hans von Celsing, Leni Ekendahl, Marianne Östlund and Anna Tenstam Declines Re-Election to the Board of Directors of PEPTONIC medical AB (publ) Apr 07
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 27 PEPTONIC medical AB (publ) to Report Q3, 2022 Results on Nov 10, 2022
Peptonic Medical Introduces the Vagivital Range of Products to the US Market Feb 17
Third quarter 2021 earnings released Nov 12
PEPTONIC Initiates Non-Exclusive Negotiations Regarding a Possible Acquisition of All Assets in CommonSense Ltd (Israel) Sep 15
Second quarter 2021 earnings released: kr0.064 loss per share (vs kr0.051 loss in 2Q 2020) Aug 21 Peptonic Medical Gets Approval to Start a Clinical Trial for the Treatment of Vaginal Fungal Infections with an Adapted Version of VagiVital AktivGel
Peptonic Medical AB (Publ) Announces Latest Clinical Study with Vagivita Jun 30
Peptonic Medical (publ) to Launch New Innovative Intimate Care Range Under Lunette Brand, Bringing Special Nordic Ingredients Down There May 27
First quarter 2021 earnings released May 14
New 90-day low: kr1.55 Feb 27 PEPTONIC medical AB (publ), Annual General Meeting, Jun 09, 2021
New 90-day low: kr1.60 Jan 28
Chief Financial Officer recently sold kr84k worth of stock Dec 25
New 90-day low: kr1.68 Dec 11
Third quarter 2020 earnings released: kr0.041 loss per share Dec 03 Peptonic to Launch the Self-Test Under the VagiVital® Brand
New 90-day low: kr1.98 Nov 24
Peptonic Medical AB Files Patent Application for the Treatment of Fungal Infections and Bacterial Vaginosis Nov 10
New 90-day high - kr2.38 Sep 03
Earnings released Aug 18
New 90-day high - kr2.24 Aug 07
PEPTONIC medical AB (publ) (NGM:PMED) exercised the option to acquire remaining 26.67% stake in Lune Group Oy Ltd for €1.2 million. Jul 08 Shareholder Returns PMED SE Pharmaceuticals SE Market 7D 0% -0.7% 1.1% 1Y -27.7% -1.4% 13.3%
See full shareholder returns
Return vs Market: PMED underperformed the Swedish Market which returned 8.6% over the past year.
Price Volatility Is PMED's price volatile compared to industry and market? PMED volatility PMED Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 9.9% Market Average Movement 5.6% 10% most volatile stocks in SE Market 11.7% 10% least volatile stocks in SE Market 3.2%
Stable Share Price: PMED has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PMED's volatility change over the past year.
About the Company PEPTONIC medical AB (publ), a pharmaceutical company, researches, develops, and sells medical treatments and lifestyle products in the field of women's health. It offers VagiVital, a hormone-free treatment for symptoms related to vaginal atrophy, such as pain during intercourse, burning, itching, and dryness, as well as moisturizing and an oil-based intimate wash. The company also provides lifestyle consumer products under the Lunette brand.
Show more PEPTONIC medical AB (publ) Fundamentals Summary How do PEPTONIC medical's earnings and revenue compare to its market cap? PMED fundamental statistics Market cap SEK 92.09m Earnings (TTM ) -SEK 31.00m Revenue (TTM ) SEK 40.52m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PMED income statement (TTM ) Revenue SEK 40.52m Cost of Revenue SEK 20.53m Gross Profit SEK 20.00m Other Expenses SEK 51.00m Earnings -SEK 31.00m
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 07, 2024
Earnings per share (EPS) -0.02 Gross Margin 49.35% Net Profit Margin -76.50% Debt/Equity Ratio 6.7%
How did PMED perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/04/29 15:10 End of Day Share Price 2024/01/31 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources PEPTONIC medical AB (publ) is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Markus Augustsson Carlsquare AB Joanna Boquist Redeye
Show 0 more analysts 
